OMNIAB, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • April 28th, 2022 • OmniAb, Inc. • Services-commercial physical & biological research • Delaware
This Indemnification Agreement (“Agreement”) is made as of ________ __, 20__ by and between OmniAb, Inc., a Delaware corporation (the “Company”), and ______________, [a member of the Board of Directors/ an officer] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnification and advancement.
Amended and Restated License Agreement This Amended and Restated License Agreement (“Agreement”) is made on May 29, 2020 by and betweenLicense Agreement • April 28th, 2022 • OmniAb, Inc. • Services-commercial physical & biological research • New York
lcagen, LLC (formerly known as Adjacent Acquisition Co., LLC; as assignee from lcagen, lnc., the party to the original License Agreement)
RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN ICAGEN, INC. AND CYSTIC FIBROSIS FOUNDATION RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT CONTENTSResearch, Development and Commercialization Agreement • April 28th, 2022 • OmniAb, Inc. • Services-commercial physical & biological research • Delaware
This Agreement (this “Agreement”) is made on this 1st day of May, 2018 and shall be effective on the Effective Date by and between Icagen, Inc. (“Icagen”), a corporation having a principal place of business at [***] acting on behalf of itself and Affiliates, and Cystic Fibrosis Foundation (“CFF”), a nonprofit corporation with its principal offices at [***], and shall become effective on the Effective Date. Icagen and CFF are each referred to herein individually as a “Party” and collectively as the “Parties”.
ANTIBODY LICENSE AGREEMENTAntibody License Agreement • April 28th, 2022 • OmniAb, Inc. • Services-commercial physical & biological research • New York
This Antibody License Agreement (“Agreement”) is entered into effective December 20, 2012 (“Effective Date”) by Open Monoclonal Technologies, Inc. (“OMT”), a Delaware corporation having its principal place of business at 2747 Ross Road, Suite A, Palo Alto, CA 94303 and CNA Development LLC (“Licensee”), a Delaware limited liability company, having its principal place of business at [***].
LAB LEASE BETWEEN EMERY STATION OFFICE II, LLC (LANDLORD) AND CRYSTAL BIOSCIENCE, INC. (TENANT) EMERY STATION NORTH Emeryville, CaliforniaLab Lease • April 28th, 2022 • OmniAb, Inc. • Services-commercial physical & biological research • California
